Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Moderate Buy” by Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has received a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $66.29.

JANX has been the topic of a number of research reports. Wedbush lifted their price target on shares of Janux Therapeutics from $53.00 to $74.00 and gave the company an “outperform” rating in a report on Wednesday, May 8th. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday, February 27th. Cantor Fitzgerald restated an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a report on Thursday, May 9th. Jonestrading initiated coverage on Janux Therapeutics in a report on Tuesday, April 16th. They set a “buy” rating and a $70.00 price objective on the stock. Finally, BTIG Research began coverage on shares of Janux Therapeutics in a report on Thursday, March 21st. They issued a “buy” rating and a $62.00 target price for the company.

Janux Therapeutics Price Performance

Shares of NASDAQ:JANX opened at $43.38 on Tuesday. The firm’s 50 day simple moving average is $48.56 and its two-hundred day simple moving average is $29.01. The company has a market capitalization of $2.25 billion, a P/E ratio of -35.56 and a beta of 3.71. Janux Therapeutics has a 1-year low of $5.65 and a 1-year high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Tuesday, May 7th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. Janux Therapeutics had a negative net margin of 762.92% and a negative return on equity of 13.49%. The company had revenue of $1.25 million for the quarter, compared to analysts’ expectations of $0.98 million. On average, sell-side analysts anticipate that Janux Therapeutics will post -1.34 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Tighe Reardon sold 822,721 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $45,043,974.75. Following the completion of the sale, the chief financial officer now directly owns 633,673 shares in the company, valued at $34,693,596.75. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total transaction of $37,081,025.25. Following the completion of the transaction, the insider now owns 3,271,216 shares in the company, valued at $179,099,076. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Tighe Reardon sold 822,721 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $54.75, for a total value of $45,043,974.75. Following the transaction, the chief financial officer now directly owns 633,673 shares in the company, valued at approximately $34,693,596.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,000,000 shares of company stock valued at $164,250,000. 35.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC increased its stake in Janux Therapeutics by 10,740.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock worth $29,000 after purchasing an additional 2,685 shares during the period. Exchange Traded Concepts LLC grew its holdings in shares of Janux Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 14,204 shares of the company’s stock worth $152,000 after purchasing an additional 3,602 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Janux Therapeutics by 82.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,743 shares of the company’s stock worth $367,000 after purchasing an additional 4,400 shares during the last quarter. ProShare Advisors LLC purchased a new position in Janux Therapeutics in the 1st quarter worth about $251,000. Finally, Lester Murray Antman dba SimplyRich purchased a new stake in Janux Therapeutics in the 1st quarter valued at about $300,000. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.